SBFM
Sunshine Biopharma Inc.
Latest price
As of Oct 26, 2026, 7:56 PM EDT · Market data by Massive
Market cap
$111.1K
Volume
91.3K
Previous close
$3.00
Day range
$2.58 – $3.11
Listed
Aug 9, 2007
Coverage
7 articles
Price performance
Recent trading
Newsroom
Latest SBFM coverage
Pre-Market Movers: DKI, FLYE, AIXI Lead the Small-Cap Scan
DKI led a group of 10 active small-cap stocks flagged for editorial review.
Midday Movers: SBFM, DKI, TOPP Lead the Small-Cap Scan
SBFM led a group of 10 active small-cap stocks flagged for editorial review.
SUNSHINE BIOPHARMA REPORTS FULL YEAR ENDED DECEMBER 31, 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced reporting of operating results for the fiscal year ended December 31, 2022 and recent highlights.
SUNSHINE BIOPHARMA SIGNS RESEARCH AGREEMENT WITH THE JEWISH GENERAL HOSPITAL TO ADVANCE THE DEVELOPMENT OF Adva-27a ANTICANCER COMPOUND
Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced the signing of a research agreement with Sir Mortimer B. Davis Jewish General Hospital, a McGill University Health Center hospital located in Montreal, Quebec, Ca
SUNSHINE BIOPHARMA ANNOUNCES SHARE REPURCHASE PROGRAM
Sunshine Biopharma Inc today announced its board of directors has authorized a share repurchase program to acquire up to $2 million of the Company’s common stock.
SUNSHINE BIOPHARMA’S ANNUAL LETTER TO SHAREHOLDERS
Sunshine Biopharma Inc. issued a letter to shareholders from Dr. Steve Slilaty, Chairman and CEO of the Company.
Sunshine Biopharma Files Patent Application Covering Recently Announced mRNA Molecules Found To Be Effective At Destroying Multidrug Resistant Cancer Cells
Montreal, Quebec, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has filed a provisional patent application in the United States covering the recently communicated mRNA molecules foun